DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Coverage details, prior authorization criteria, copay ranges, and appeal strategy for 2026. Verified May 1, 2026.
Cigna commercial plans cover GLP-1s with PA. Tightened step-therapy requirements in 2025 — phentermine + lifestyle program prerequisite on most plans. ESI pharmacy benefit manager.
Cigna requires the following before approving Wegovy:
Top denial patterns we see in 2026 based on appeal-claim data:
Cigna 2025 step therapy update — phentermine contraindication (hypertension, cardiovascular hx) bypasses step. Document contraindication in clinical notes.
myCigna portal → Pharmacy Appeal → 72h expedited if medical urgency documented.
Wegovy (semaglutide 2.4mg) carries the following FDA-approved indications. Off-label use is the #1 PA denial reason — ensure your prescribing diagnosis matches one of these.
Coverage details verified May 1, 2026 against Cigna formulary documentation. Formulary changes happen quarterly — always verify against your specific plan before prescribing.